Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including cardio, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
stocks
Two new ASX names added to our Global Best Stock Ideas
Our full global list includes 78 companies from around the world.
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.30 | 71.60 | -0.79% |
| CAC 40 | 8,020.31 | 27.38 | -0.34% |
| DAX 40 | 25,864.62 | 116.47 | -0.45% |
| Dow JONES (US) | 51,786.72 | 197.26 | -0.38% |
| FTSE 100 | 10,638.43 | 122.90 | -1.14% |
| HKSE | 23,472.27 | 53.70 | -0.23% |
| NASDAQ | 25,372.01 | 207.65 | 0.83% |
| Nikkei 225 | 60,835.36 | 2,246.50 | -3.56% |
| NZX 50 Index | 13,771.31 | 51.05 | 0.37% |
| S&P 500 | 7,568.92 | 27.52 | 0.36% |
| S&P/ASX 200 | 8,816.80 | 70.00 | -0.79% |
| SSE Composite Index | 3,597.47 | 10.63 | -0.29% |